Advertisement
Australia markets closed
  • ALL ORDS

    7,932.00
    +25.40 (+0.32%)
     
  • AUD/USD

    0.6533
    -0.0037 (-0.56%)
     
  • ASX 200

    7,664.10
    +26.70 (+0.35%)
     
  • OIL

    82.78
    +0.15 (+0.18%)
     
  • GOLD

    2,327.60
    -30.10 (-1.28%)
     
  • Bitcoin AUD

    95,873.21
    -1,031.25 (-1.06%)
     
  • CMC Crypto 200

    1,289.60
    -49.47 (-3.69%)
     

Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024

CAMBRIDGE, Mass., April 11, 2024--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates.

The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411131491/en/

Contacts

Investor Contact
Ashley Kaplowitz
786-252-1419
ashley.kaplowitz@sagerx.com

Media Contact
Matthew Henson
917-930-7147
matthew.henson@sagerx.com